The type 1 IGF receptor (IGF-IR) is activated by two ligands, IGF-1 and IGF-2, and by insulin at supraphysiological concentrations. It plays a significant role in the growth of normal and abnormal ...
The treatment was approved by China’s National Medical Products Administration (NMPA) and is China's first, and the world’s ...
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, ...
Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of ...
Assistant Professor of Biology Emrah Altindis has been awarded a five-year, $2.5-million grant from the National Institutes of Health to advance his research on viral insulins into the understanding ...
Hosted on MSN2mon
Rare mutation that causes short stature may shed light on ageingPeople with a rare genetic mutation that causes short stature and may also make them live longer are helping shed light on the causes of ageing. Those with the unusual gene variant have several ...
In this comprehensive project, our aim is to comprehend how VILPs interact with the insulin/IGF-1 system, influencing receptors, downstream signaling, and related functions. We've already uncovered ...
a recombinant anti-insulin-like growth factor 1 receptor (IGF-1R) antibody) for the treatment of thyroid eye disease (TED). As China's first and the world's second approved IGF-1R antibody drug ...
Innovent Biologics’ Sycume receives China NMPA approval for treatment of thyroid eye disease: San Francisco Monday, March 17, 2025, 16:00 Hrs [IST] Innovent Biologics, Inc, a wo ...
("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback